Serum vitamin D levels of patients with oral squamous cell carcinoma (OSCC) and expression of vitamin D receptor in oral precancerous lesions and OSCC

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 20, Issue 2, 2015, Pages e188-e195

  Grimm, Martin ^a   Cetindis, Marcel ^a   Biegner, Thorsten ^a   Lehman, Max ^a   Munz, Adelheid ^a   Teriete, Peter ^b   Reinert, Siegmar ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Apoptosis; Chemoprevention; Leukoplakia; Lichen planus; Multistep carcinogenesis; Oral cancer; Oral precancer; Serum 25(OH)D3; Vitamin D receptor

Indexed keywords

CALCIFEDIOL; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR;

APOPTOSIS; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MALE; MOUTH SQUAMOUS CELL CARCINOMA; RADIOIMMUNOASSAY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; BIOSYNTHESIS; BLOOD; METABOLISM; MOUTH TUMOR; PRECANCER; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MALE; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; RECEPTORS, CALCITRIOL; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 84923862985     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: 10.4317/medoral.20368     Document Type: Article

References (56)

1. Choudhari SK, Chaudhary M, Gadbail AR, Sharma A, Tekade S. Oxidative and antioxidative mechanisms in oral cancer and precancer: a review. Oral Oncol. 2014;50:10-8.
2. Tanaka T, Tanaka M, Tanaka T. Oral carcinogenesis and oral cancer chemoprevention: a review. Patholog Res Int. 2011;2011:431246.
3. Driemel O, Hertel K, Reichert TE, Kosmehl H. Current classification of precursor lesions of oral squamous cell carcinoma principles of the WHO classification 2005. Mund Kiefer Gesichtschir. 2006;10:89-93.
4. Grimm M. Prognostic value of clinicopathological parameters and outcome in 484 patients with oral squamous cell carcinoma: microvascular invasion (V+) is an independent prognostic factor for OSCC. Clinical & translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2012;14:870-80.
5. Perez-Sayans M, Suarez-Penaranda JM, Pilar GD, Barros-Angueira F, Gandara-Rey JM, Garcia-Garcia A. Hypoxia-inducible factors in OSCC. Cancer letters. 2011;313:1-8.
6. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45:487-98.
7. Sinha N, Mukhopadhyay S, Das DN, Panda PK, Bhutia SK. Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in oral cancer. Oral Oncol. 2013;49:854-62.
8. Grimm M, Schmitt S, Teriete P, Biegner T, Stenzl A, Hennenlotter J, et al. A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer. 2013;13:569.
9. Richard V, Sebastian P, Nair MG, Nair SN, Malieckal TT, Santhosh Kumar TR, et al. Multiple drug resistant, tumorigenic stemlike cells in oral cancer. Cancer Lett. 2013;338:300-16.
10. Nair R, Maseeh A. Vitamin D: The “sunshine” vitamin. J Pharmacol Pharmacother. 2012;3:118-26.
11. Grimm M, Alexander D, Munz A, Hoffmann J, Reinert S. Is 1,25-dihydroxyvitamin D3 receptor expression a potential Achilles’ heel of CD44+ oral squamous cell carcinoma cells?. Target Oncol. 2013;8:189-201.
12. Kornfehl J, Formanek M, Temmel A, Knerer B, Willheim M. Antiproliferative effects of the biologically active metabolite of vitamin D3 (1,25 [OH]2 D3) on head and neck squamous cell carcinoma cell lines. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies. 1996;253:341-4.
13. Kulbersh JS, Day TA, Gillespie MB, Young MR. 1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells. Otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2009;140:235-40.
14. Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, Leonetti JP, et al. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer. 1997;74:69-74.
15. Lu L, Qiu J, Liu S, Luo W. Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Molecular cancer therapeutics. 2008;7:1268-74.
16. Hager G, Kornfehl J, Knerer B, Weigel G, Formanek M. Molecular analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence of 1,25(OH)2 vitamin D3 and its analogs. Acta oto-laryngologica. 2004;124:90-6.
17. Satake K, Takagi E, Ishii A, Kato Y, Imagawa Y, Kimura Y, et al. Anti-tumor effect of vitamin A and D on head and neck squamous cell carcinoma. Auris Nasus Larynx. 2003;30:403-12.
18. Prudencio J, Akutsu N, Benlimame N, Wang T, Bastien Y, Lin R, et al. Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma. Journal of the National Cancer Institute. 2001;93:745-53.
19. Meier JD, Enepekides DJ, Poirier B, Bradley CA, Albala JS, Farwell DG. Treatment with 1-alpha,25-dihydroxyvitamin D3 (vitamin D3) to inhibit carcinogenesis in the hamster buccal pouch model. Archives of otolaryngology--head & neck surgery. 2007;133:1149-52.
20. Osafi J, Hejazi A, Stutz DD, Keiserman MA, Bergman CJ, Kingsley K. Differential effects of 1,25-dihydroxyvitamin D(3) on oral squamous cell carcinomas in vitro. J Diet Suppl. 2014;11:145-54.
21. Dalirsani Z, Farajnia S, Javadzadeh Y, Mehdipour M, Koozegari S. The effects of 5-fluorouracil alone and in combination with 13-cis retinoic acid and vitamin D3 on human oral squamous cell carcinoma lines. J Contemp Dent Pract. 2012;13:345-50.
22. Tuohimaa P, Lou YR. Optimal serum calcidiol concentration for cancer prevention. Anticancer Res. 2012;32:373-81.
23. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr. 2008;87:1087S-91S.
24. Walker RA. Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006;49:406-10.
25. Alipour S, Hadji M, Hosseini L, Omranipour R, Saberi A, Seifollahi A, et al. Levels of serum 25-hydroxy-vitamin d in benign and malignant breast masses. Asian Pac J Cancer Prev. 2014;15:129-32.
26. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755-68.
27. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23-8.
28. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle. 2007;6:2332-8.
29. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-7.
30. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843-50.
31. So JY, Lee HJ, Smolarek AK, Paul S, Wang CX, Maehr H, et al. A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol Pharmacol. 2011;79:360-7.
32. Pervin S, Hewison M, Braga M, Tran L, Chun R, Karam A, et al. Down-regulation of vitamin D receptor in mammospheres: implications for vitamin D resistance in breast cancer and potential for combination therapy. PLoS One. 2013;8:e53287.
33. Souza RF, Krishnan K, Spechler SJ. Acid, bile, and CDX: the ABCs of making Barrett’s metaplasia. Am J Physiol Gastrointest Liver Physiol. 2008;295:G211-8.
34. Jeon J, Luebeck EG, Moolgavkar SH. Age effects and temporal trends in adenocarcinoma of the esophagus and gastric cardia (United States). Cancer Causes Control. 2006;17:971-81.
35. von Rahden BH, Kircher S, Lazariotou M, Reiber C, Stuermer L, Otto C, et al. LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett’s Esophagus? J Exp Clin Cancer Res. 2011;30:23.
36. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets. 2009;9:320-40.
37. Sundaram K, Sambandam Y, Tsuruga E, Wagner CL, Reddy SV. 1alpha,25-dihydroxyvitamin D3 modulates CYP2R1 gene expression in human oral squamous cell carcinoma tumor cells. Horm Cancer. 2014;5:90-7.
38. Guyton KZ, Kensler TW, Posner GH. Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu Rev Pharmacol Toxicol. 2001;41:421-42.
39. Tretli S, Schwartz GG, Torjesen PA, Robsahm TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control. 2012;23:363-70.
40. Anderson LN, Cotterchio M, Vieth R, Knight JA. Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. Am J Clin Nutr. 2010;91:1699-707.
41. Heaney RP. Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008;3:1535-41.
42. Anand S, Rollakanti KR, Horst RL, Hasan T, Maytin EV. Combination of oral vitamin D3 with photodynamic therapy enhances tumor cell death in a murine model of cutaneous squamous cell carcinoma. Photochem Photobiol. 2014;90:1126-35.
43. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6:963-8.
44. Angadi PV, Savitha JK, Rao SS, Sivaranjini Y. Oral field cancerization: current evidence and future perspectives. Oral Maxillofac Surg. 2012;16:171-80.
45. Leon X, del Prado Venegas M, Orus C, Lopez M, Garcia J, Quer M. Influence of the persistence of tobacco and alcohol use in the appearance of second neoplasm in patients with a head and neck cancer. A case-control study. Cancer Causes Control. 2009;20:645-52.
46. Malodobra-Mazur M, Paduch A, Lebioda A, Konopacka M, Rogolinski J, Szymczyk C, et al. VDR gene single nucleotide polymorphisms and their association with risk of oral cavity carcinoma. Acta Biochim Pol. 2012;59:627-30.
47. Costa EM, Feldman D. Measurement of 1,25-dihydroxyvitamin D3 receptor turnover by dense amino acid labeling: changes during receptor up-regulation by vitamin D metabolites. Endocrinology. 1987;120:1173-8.
48. Wiese RJ, Uhland-Smith A, Ross TK, Prahl JM, DeLuca HF. Upregulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. The Journal of biological chemistry. 1992;267:20082-6.
49. Mangelsdorf DJ, Pike JW, Haussler MR. Avian and mammalian receptors for 1,25-dihydroxyvitamin D3: in vitro translation to characterize size and hormone-dependent regulation. Proceedings of the National Academy of Sciences of the United States of America. 1987;84:354-8.
50. Lehmann B. HaCaT cell line as a model system for vitamin D3 metabolism in human skin. The Journal of investigative dermatology. 1997;108:78-82.
51. Reichrath J, Rafi L, Muller SM, Mink D, Reitnauer K, Tilgen W, et al. Immunohistochemical analysis of 1,25-dihydroxyvitamin D3 receptor in cervical carcinoma. Histochem J. 1998;30:561-7.
52. Gugatschka M, Kiesler K, Obermayer-Pietsch B, Groselj-Strele A, Griesbacher A, Friedrich G. Vitamin D status is associated with disease-free survival and overall survival time in patients with squamous cell carcinoma of the upper aerodigestive tract. Eur Arch Otorhinolaryngol. 2011;268:1201-4.
53. Pludowski P, Grant WB, Bhattoa HP, Bayer M, Povoroznyuk V, Rudenka E, et al. Vitamin D Status in Central Europe. Int J Endocrinol. 2014;2014:589587.
54. Arem H, Weinstein SJ, Horst RL, Virtamo J, Yu K, Albanes D, et al. Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men. Cancer Epidemiol Biomarkers Prev. 2011;20:1178-84.
55. Yuan FN, Valiyaparambil J, Woods MC, Tran H, Pant R, Adams JS, et al. Vitamin D signaling regulates oral keratinocyte proliferation in vitro and in vivo. Int J Oncol. 2014;44:1625-33.
56. Afzal S, Bojesen SE, Nordestgaard BG. Low plasma 25-hydroxyvitamin D and risk of tobacco-related cancer. Clin Chem. 2013;59:771-80.